Ebvia
Advancing multi-target treatments for COVID-19 & pulmonary disorders.
San Francisco, United States
3 employees
Pre-Seed
Biotechnology, Care Economy +2
General Information
San Francisco, United States
BounceWatch is an independent company data service, not affiliated with Ebvia. To contact Ebvia, visit ebvia.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Ebvia compare?
A PDF of Ebvia and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Ebvia soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Biotechnology
About Ebvia
Business keywords: COVID-19 treatment, pulmonary disorders, outpatient treatment, medication candidate, SARS-COV-2, delta variant, influenza strains, animal models, clinical trials, innovation, efficacy, private company, investor interest, startup
Funding Rounds & Investors (1)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Pre Seed Round | Undisclosed | 1 |
George Burke
|
01 Jan 2022 |
Ebvia Alternatives & Competitors
View All Alternatives
Empowering patients with advanced pulmonary delivery therapies for central nervous system and respir...
DEVELOPING INNOVATIVE TREATMENTS FOR GENITOURINARY TRACT DISORDERS
Developing novel medicines to provide better treatment options for patients with life-threatening pu...
FAQ About Ebvia
Source: BounceWatch company record for Ebvia, https://bouncewatch.com/company/ebvia, updated 11 October 2024. When citing, please name BounceWatch and link this page.
